Login to Your Account


Regulatory filings this year
Valeant Pharmaceuticals International Inc. picked up the brodalumab torch dropped in May by Amgen Inc., inking an exclusive license with Astrazeneca plc to develop and commercialize the interleukin (IL)-17 inhibitor in moderate to severe plaque psoriasis and psoriatic arthritis. more »

Our Habitat for All Things Science
No brainer: FTO's effects on weight are peripheral effect

In genomewide association studies (GWAS), a variant in the gene FTO is the strongest obesity-correlated signal in the human genome.

Since it was first flagged by GWAS seven years ago, though, why FTO is so strongly linked to obesity has remained a puzzle.

Now, scientists have dissected the cellular circuitry that is affected by FTO. Their work both suggests new obesity targets and could serve as a general roadmap for how to understand the effects of variants in noncoding regions of the genome.

READ MORE »